NSE: SYNGENE · 29 October 2026
- Syngene International has risen 10.77% over 3 trading sessions; today's move is -2.98%.
- Syngene reported a sequential revenue increase of 13% for Q2 FY27 to ₹833 crore, with an operating EBITDA margin of 18% and profit after tax before exceptional items at ₹38 crore. The company secured its first manufacturing agreement for the Bayview biologics facility in the U.S. and expanded its integrated drug discovery leadership under Dr. Jayashree Aiyar. However, on a year-on-year basis, revenue declined 9% due to lower Zoetis revenues and forex hedge losses.
- Trading volume was 1.39 times the 20-day average daily volume.
Syngene International share price: 10.77% rise over 3 trading sessions
Syngene International Ltd. (SYNGENE) declined 2.98% today, settling at ₹398.60 after moving within a intraday range of ₹396.20 to ₹414.00.
The broader market and sector showed positive momentum, with the Nifty benchmark gaining 1.05% and the Nifty Pharma sector index advancing 0.64%. Syngene's pullback ran counter to the positive close of its sectoral index, pointing to stock-specific price adjustments following its recent strong run.
The move follows the company's recent Q2 FY27 financial disclosures released on October 27, 2026, which reported sequential revenue growth of 13% to ₹833 crore and an operating EBITDA margin of 18%, alongside several leadership and management changes. While these operational updates provide medium-term context, the day's downward movement appears consistent with profit-taking after the stock's prior sessions posted multi-percentage gains.
33.32 lakh shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 23.93 lakh shares (1.39 times). The five-day average daily volume was 71.57 lakh shares. Separately, the NSE report for 28 October 2026 showed 45.87 lakh shares delivered, representing 13.91% of that day’s traded volume. The same report recorded 447,917 trades.
The stock retreated by 2.98% despite a positive close in the Nifty Pharma sector, following strong prior session returns of 12.19% and 14.17% over the last two and three trading days. Cash volume reached 1.39 times the 20-day average, supported by a delivery quantity of 4,586,751 shares representing 13.91% of total traded volume on October 28, 2026, pointing to normal profit-taking and technical retracement.
Latest Company Developments
Syngene reported a sequential revenue increase of 13% for Q2 FY27 to ₹833 crore, with an operating EBITDA margin of 18% and profit after tax before exceptional items at ₹38 crore. The company secured its first manufacturing agreement for the Bayview biologics facility in the U.S. and expanded its integrated drug discovery leadership under Dr. Jayashree Aiyar. However, on a year-on-year basis, revenue declined 9% due to lower Zoetis revenues and forex hedge losses.
Quarterly earnings results and new contract wins provide essential fundamental baselines for evaluating the company's CDMO growth trajectory and margin recovery.
The company announced multiple executive changes, including the resignation of Ajay Tandon as Head of Strategy and Corporate Development effective October 30, 2026, and the departure of Chief Financial Officer Deepak Jain, who will step down after a transition period. Additionally, chemistry and biology heads Subhendu Kumar and Priyaranjan Pattanaik transitioned from senior management personnel to non-SMP categories.
Executive departures and role restructuring highlight ongoing organizational realignment within key corporate and scientific leadership positions.
a press release dated October 27, 2026, titled "Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points".
Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
a press release dated October 27, 2026, titled "Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 27.10% on 30 September 2026. This compares with 25.78% on 30 June 2026, a change of +1.32 percentage points.
The filing reported 28 MF/UTI holders.
What to Watch Next
- Execution progress on the newly signed Bayview biologics facility manufacturing agreement with a large pharmaceutical customer
- Transition timeline and appointment process for the incoming Chief Financial Officer
- Realization of benefits from completed manpower-related cost-optimization initiatives over upcoming quarters
- Volume trends and cash delivery participation relative to the 20-day average volume
Other Dated Coverage
- Syngene International Share Price Today: Rises 12.55% in 2 Trading Sessions | 28 October 2026 — 28 October 2026
- Syngene International Share Price Today: Why SYNGENE Is Rising 1.76% | 27 October 2026 — 27 October 2026
More Syngene International news and dated analysis →
Frequently Asked Questions
What is the latest Syngene International company news?
Syngene reported a sequential revenue increase of 13% for Q2 FY27 to ₹833 crore, with an operating EBITDA margin of 18% and profit after tax before exceptional items at ₹38 crore. The company secured its first manufacturing agreement for the Bayview biologics facility in the U.S. and expanded its integrated drug discovery leadership under Dr. Jayashree Aiyar. However, on a year-on-year basis, revenue declined 9% due to lower Zoetis revenues and forex hedge losses.
How strong was Syngene International’s trading volume?
33.32 lakh shares traded, 1.39 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.